Longeveron expects ELPIS II HLHS data in mid-september while cash runway extends into Q4 2026
Earnings Call Insights: Longeveron (LGVN) Q2 2026 MANAGEMENT VIEW * "Longeveron is approaching a series of potentially transformative milestones across our 4 stem cell therapy development programs" (CEO & Director Stephen Willard), while reiterating laromestrocel development across "Hypoplastic Left Heart Syndrome, Alzheimer's disease, pediatric …